The pharmacovigilance market in Denmark is expected to reach a projected revenue of US$ 145.9 million by 2033. A compound annual growth rate of 5.8% is expected of Denmark pharmacovigilance market from 2026 to 2033.
The Denmark pharmacovigilance market generated a revenue of USD 91.1 million in 2025 and is expected to reach USD 145.9 million by 2033.
The Denmark market is expected to grow at a CAGR of 5.8% from 2026 to 2033.
In terms of segment, phase iv was the largest revenue generating product life cycle in 2025.
Phase I is the most lucrative product life cycle segment registering the fastest growth during the forecast period.
Pharmacovigilance market data book summary
Market revenue in 2025
USD 91.1 million
Market revenue in 2033
USD 145.9 million
Growth rate
5.8% (CAGR from 2026 to 2033)
Largest segment
Phase iv
Fastest growing segment
Phase I
Historical data
2021 - 2024
Base year
2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Pre Clinical, Phase I, Phase II, Phase III, Phase IV
Key market players worldwide
Accenture PLC Class A, IQVIA Holdings Inc, Cognizant Technology Solutions Corp Class A, Linical Americas, International Business Machines Corp, Labcorp Holdings Inc, ArisGlobal, Capgemini SE, ITClinical, Icon PLC, TAKE Solutions, PAREXEL, Wipro Ltd ADR, United Biosource Corporation, FMD K&L, BioClinica
Other key industry trends
In terms of revenue, Denmark accounted for 1.1% of the global pharmacovigilance market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Europe, Germany pharmacovigilance market is projected to lead the regional market in terms of revenue in 2033.
Spain is the fastest growing regional market in Europe and is projected to reach USD 271.9 million by 2033.
The pharmacovigilance market in Denmark is expected to grow over the forecast period owing to the increased use of biologicals and biosimilars. According to a study published by the European Journal of Clinical Pharmacology in 2021, Denmark had the most thorough and fastest uptake of trastuzumab biosimilar compared to other European nations.
Moreover, the market share of trastuzumab increased by 90% in the country just after 3 months of its implementation.
The government's funding and support of digital health projects have accelerated PV development & adoption in the country. For instance, in 2022, Denmark was ranked 7th in the World Index of Healthcare Innovation with an overall score of 52.41, moving from 11th in 2021 and 14th in 2020. This number indicates growing innovations and advancements in healthcare technologies in the country.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Pharmacovigilance Market Outlook will help companies and investors design strategic landscapes.
Phase Iv was the largest segment with a revenue share of 81.67% in 2025.
Horizon Databook has segmented the Denmark pharmacovigilance market based on pre clinical, phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2021 to 2033.
The pharmacovigilance market in Denmark is expected to grow over the forecast period owing to the increased use of biologicals and biosimilars. According to a study published by the European Journal of Clinical Pharmacology in 2021, Denmark had the most thorough and fastest uptake of trastuzumab biosimilar compared to other European nations.
Moreover, the market share of trastuzumab increased by 90% in the country just after 3 months of its implementation.
The government's funding and support of digital health projects have accelerated PV development & adoption in the country. For instance, in 2022, Denmark was ranked 7th in the World Index of Healthcare Innovation with an overall score of 52.41, moving from 11th in 2021 and 14th in 2020. This number indicates growing innovations and advancements in healthcare technologies in the country.
Denmark Pharmacovigilance Market Product Life Cycle Outlook (Revenue, USD Million , 2021-2033)
Pre Clinical
Phase I
Phase II
Phase III
Phase IV
Denmark Pharmacovigilance Market Service Provider Outlook (Revenue, USD Million , 2021-2033)
In House
Contract outsourcing
Denmark Pharmacovigilance Market Type Outlook (Revenue, USD Million , 2021-2033)
Spontaneous reporting
Intensified ADR Reporting
Targeted Spontaneous Reporting
Cohort Event Monitoring
EHR Mining
Denmark Pharmacovigilance Market End Use Outlook (Revenue, USD Million , 2021-2033)
Pharmaceuticals
Biotechnology Companies
Medical Device Manufacturers
Others
Denmark Pharmacovigilance Market Therapeutic Area Outlook (Revenue, USD Million , 2021-2033)
Oncology
Neurology
Cardiology
Respiratory Systems
Others
Denmark Pharmacovigilance Market Process Flow Outlook (Revenue, USD Million , 2021-2033)
Case Data Management
Signal Detection
Risk Management System
Reasons to subscribe to Pharmacovigilance Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Pharmacovigilance Market Outlook databook
Our clientele includes a mix of Pharmacovigilance Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Denmark Pharmacovigilance Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Denmark Pharmacovigilance Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.